Recreational nitrous oxide and thrombotic events: a case series.

B12 DEFICIENCY CLINICAL NEUROLOGY SINUS THROMBOSIS

Journal

BMJ neurology open
ISSN: 2632-6140
Titre abrégé: BMJ Neurol Open
Pays: England
ID NLM: 101775450

Informations de publication

Date de publication:
2024
Historique:
accepted: 02 03 2024
medline: 17 5 2024
pubmed: 17 5 2024
entrez: 17 5 2024
Statut: epublish

Résumé

The study aimed to elucidate the prevalence of nitrous oxide (N2O) usage in patients with unexplained venous thromboembolism (VTE), highlighting the potential association with hyperhomocysteinaemia (HHcy). We conducted a retrospective study at the Royal London Hospital, examining cases of N2O-related VTE from March to August 2023. Among 50 patients identified, four (8%) had recent unprovoked VTE. Patient data were collected based on N2O ambulatory emergency care pathway admissions. Among the 50 patients identified, four (8%) had recent or concurrent VTE. Three were male (75%), with an ethnic distribution of 50% Asian or Asian British and 50% Black or Black British. Patients were distributed across quintiles of the index of multiple deprivation. All had actual or functional vitamin B12 deficiency. The association between N2O use and VTE requires further investigation, though a plausible mechanism involving HHcy has been proposed. Clinicians should be vigilant for VTE in N2O users, especially those presenting with unexplained symptoms. VTE prophylaxis may be worth considering, particularly if continued exposure to nitrous oxide is anticipated. N2O misuse may increase the risk of VTE, warranting attention from healthcare providers. Further research is needed to elucidate this association and inform preventive strategies. Public awareness about the risks of N2O remains essential.

Sections du résumé

Background UNASSIGNED
The study aimed to elucidate the prevalence of nitrous oxide (N2O) usage in patients with unexplained venous thromboembolism (VTE), highlighting the potential association with hyperhomocysteinaemia (HHcy).
Methods UNASSIGNED
We conducted a retrospective study at the Royal London Hospital, examining cases of N2O-related VTE from March to August 2023. Among 50 patients identified, four (8%) had recent unprovoked VTE. Patient data were collected based on N2O ambulatory emergency care pathway admissions.
Results UNASSIGNED
Among the 50 patients identified, four (8%) had recent or concurrent VTE. Three were male (75%), with an ethnic distribution of 50% Asian or Asian British and 50% Black or Black British. Patients were distributed across quintiles of the index of multiple deprivation. All had actual or functional vitamin B12 deficiency.
Discussion UNASSIGNED
The association between N2O use and VTE requires further investigation, though a plausible mechanism involving HHcy has been proposed. Clinicians should be vigilant for VTE in N2O users, especially those presenting with unexplained symptoms. VTE prophylaxis may be worth considering, particularly if continued exposure to nitrous oxide is anticipated.
Conclusion UNASSIGNED
N2O misuse may increase the risk of VTE, warranting attention from healthcare providers. Further research is needed to elucidate this association and inform preventive strategies. Public awareness about the risks of N2O remains essential.

Identifiants

pubmed: 38757110
doi: 10.1136/bmjno-2023-000619
pii: bmjno-2023-000619
pmc: PMC11097798
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e000619

Informations de copyright

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: AN reports grants from the Queen Mary Impact Fund and Tower Hamlets Council related to nitrous oxide educational programmes and clinical service development. DM leads the educational campaign N2O: Know the Risks. All other authors declare no competing interests.

Auteurs

Marta Patyjewicz (M)

Royal London Hospital, Barts Health NHS Trust, London, UK.
Centre of Preventive Neurology, Wolfson Institute of Population Health, Queen Mary University of London, London, UK.

Devan Mair (D)

Royal London Hospital, Barts Health NHS Trust, London, UK.
Queen Mary University of London, London, UK.

Safiya A Zaloum (SA)

Royal London Hospital, Barts Health NHS Trust, London, UK.
Queen Mary University of London, London, UK.

Barbara Onen (B)

Royal London Hospital, Barts Health NHS Trust, London, UK.

Joseph Walton (J)

Royal London Hospital, Barts Health NHS Trust, London, UK.

Ruth Dobson (R)

Royal London Hospital, Barts Health NHS Trust, London, UK.
Centre of Preventive Neurology, Wolfson Institute of Population Health, Queen Mary University of London, London, UK.

Christine Joerres (C)

Royal London Hospital, Barts Health NHS Trust, London, UK.

Apeksha Madhusudan Shah (AM)

Royal London Hospital, Barts Health NHS Trust, London, UK.

Peter MacCallum (P)

Royal London Hospital, Barts Health NHS Trust, London, UK.
Centre of Preventive Neurology, Wolfson Institute of Population Health, Queen Mary University of London, London, UK.

Thomas H Massey (TH)

Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK.
UK-Dementia Research Institute, Cardiff University, Cardiff, UK.

Tadbir Bariana (T)

Royal London Hospital, Barts Health NHS Trust, London, UK.

Veronica White (V)

Royal London Hospital, Barts Health NHS Trust, London, UK.

Sarah A De Freitas (SA)

Royal London Hospital, Barts Health NHS Trust, London, UK.

Alastair Noyce (A)

Royal London Hospital, Barts Health NHS Trust, London, UK.
Centre of Preventive Neurology, Wolfson Institute of Population Health, Queen Mary University of London, London, UK.

Classifications MeSH